Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2018-07-17 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CONFLANS SAINTE HONORINE (78700), Yvelines
SELARL NOUVELLE PHARMACIE CARNOT : revenue, balance sheet and financial ratios
SELARL NOUVELLE PHARMACIE CARNOT is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CONFLANS SAINTE HONORINE (78700),
this company of category PME
shows in 2024 a revenue of 4.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL NOUVELLE PHARMACIE CARNOT (SIREN 841127400)
Indicator
2025
2024
2023
2022
2021
2020
2019
Revenue
N/C
4 050 666 €
3 554 979 €
N/C
N/C
N/C
N/C
Net income
222 780 €
213 734 €
171 472 €
201 807 €
204 969 €
162 681 €
81 581 €
EBITDA
N/C
343 062 €
281 037 €
N/C
N/C
N/C
N/C
Net margin
N/C
5.3%
4.8%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL NOUVELLE PHARMACIE CARNOT generates positive net income of 223 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2025: 82 k€ -> 223 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
222 780 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 84%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
84.453%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
43.585%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL NOUVELLE PHARMACIE CARNOT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
2025
Debt ratio
1049.604
509.019
291.575
193.324
186.31
123.959
84.453
Financial autonomy
7.827
14.971
22.993
30.235
29.122
35.804
43.585
Repayment capacity
None
None
None
None
7.379
5.098
None
Cash flow / Revenue
None%
None%
None%
None%
5.117%
5.609%
None%
Sector positioning
Debt ratio
84.452025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average-14 pts over 3 years
In 2025, the debt ratio of SELARL NOUVELLE PHARMACIE... (84.45) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
43.59%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average+12 pts over 3 years
In 2025, the financial autonomy of SELARL NOUVELLE PHARMACIE... (43.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
5.1 years2024
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Average-14 pts over 2 years
In 2024, the repayment capacity of SELARL NOUVELLE PHARMACIE... (5.10) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 148.13. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
148.135
Liquidity indicators evolution SELARL NOUVELLE PHARMACIE CARNOT
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
176.104
190.547
202.584
209.242
141.79
140.308
148.135
Interest coverage
None
None
None
None
7.735
5.382
None
Sector positioning
Liquidity ratio
148.132025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average+5 pts over 3 years
In 2025, the liquidity ratio of SELARL NOUVELLE PHARMACIE... (148.13) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
5.38x2024
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good-11 pts over 2 years
In 2024, the interest coverage of SELARL NOUVELLE PHARMACIE... (5.4x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL NOUVELLE PHARMACIE CARNOT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
441 102 €
569 443 €
0 €
Inventory turnover (days)
0
0
0
0
37
36
0
Customer payment term (days)
0
0
0
0
5
3
0
Supplier payment term (days)
0
0
0
0
43
47
0
Positioning of SELARL NOUVELLE PHARMACIE CARNOT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL NOUVELLE PHARMACIE CARNOT is estimated at
3 538 886 €
(range 2 401 505€ - 5 553 000€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
2401k€3538k€5553k€
3 538 886 €Range: 2 401 505€ - 5 553 000€
NAF 5 année 2025
Valuation method used
Net Income Multiple
222 780 €
×
15.9x
=3 538 887 €
Range: 2 401 505€ - 5 553 001€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL NOUVELLE PHARMACIE CARNOT with other companies in the same sector:
Frequently asked questions about SELARL NOUVELLE PHARMACIE CARNOT
What is the revenue of SELARL NOUVELLE PHARMACIE CARNOT ?
The revenue of SELARL NOUVELLE PHARMACIE CARNOT in 2024 is 4.1 M€.
Is SELARL NOUVELLE PHARMACIE CARNOT profitable?
Yes, SELARL NOUVELLE PHARMACIE CARNOT generated a net profit of 223 k€ in 2025.
Where is the headquarters of SELARL NOUVELLE PHARMACIE CARNOT ?
The headquarters of SELARL NOUVELLE PHARMACIE CARNOT is located in CONFLANS SAINTE HONORINE (78700), in the department Yvelines.
Where to find the tax return of SELARL NOUVELLE PHARMACIE CARNOT ?
The tax return of SELARL NOUVELLE PHARMACIE CARNOT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL NOUVELLE PHARMACIE CARNOT operate?
SELARL NOUVELLE PHARMACIE CARNOT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart